ValuEngine Downgrades RXi Pharmaceuticals (RXII) to Hold

RXi Pharmaceuticals (NASDAQ:RXII) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, October 17th.

Separately, HC Wainwright initiated coverage on shares of RXi Pharmaceuticals in a research report on Monday, July 9th. They issued a “buy” rating and a $3.00 price target on the stock.

Shares of RXII traded down $0.05 during mid-day trading on Wednesday, hitting $0.43. 5,210,649 shares of the company’s stock were exchanged, compared to its average volume of 1,094,214. RXi Pharmaceuticals has a twelve month low of $0.40 and a twelve month high of $7.70. The firm has a market cap of $1.93 million, a price-to-earnings ratio of -0.10 and a beta of 2.07.

RXi Pharmaceuticals (NASDAQ:RXII) last posted its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.16. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.02 million. Research analysts anticipate that RXi Pharmaceuticals will post -1.55 EPS for the current year.

An institutional investor recently bought a new position in RXi Pharmaceuticals stock. SG Americas Securities LLC acquired a new position in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned 2.78% of RXi Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.87% of the company’s stock.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Featured Article: What factors cause inflation to rise?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply